BR0314767A - Nanocápsulas lipidìcas furtivas, processos para a preparação das mesmas e uso das mesmas como um veìculo para princìpio(s) ativo(s) - Google Patents

Nanocápsulas lipidìcas furtivas, processos para a preparação das mesmas e uso das mesmas como um veìculo para princìpio(s) ativo(s)

Info

Publication number
BR0314767A
BR0314767A BR0314767-3A BR0314767A BR0314767A BR 0314767 A BR0314767 A BR 0314767A BR 0314767 A BR0314767 A BR 0314767A BR 0314767 A BR0314767 A BR 0314767A
Authority
BR
Brazil
Prior art keywords
lipid
vehicle
preparation
processes
active ingredient
Prior art date
Application number
BR0314767-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Didier Hoarau
Pascal Delmas
Jean-Christophe Leroux
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0207175A external-priority patent/FR2840532B1/fr
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Publication of BR0314767A publication Critical patent/BR0314767A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0314767-3A 2002-06-11 2003-06-11 Nanocápsulas lipidìcas furtivas, processos para a preparação das mesmas e uso das mesmas como um veìculo para princìpio(s) ativo(s) BR0314767A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0207175A FR2840532B1 (fr) 2002-06-11 2002-06-11 Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)
US42111202P 2002-09-09 2002-09-09
PCT/IB2003/003213 WO2003103822A2 (en) 2002-06-01 2003-06-11 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)

Publications (1)

Publication Number Publication Date
BR0314767A true BR0314767A (pt) 2005-07-26

Family

ID=29738029

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314767-3A BR0314767A (pt) 2002-06-11 2003-06-11 Nanocápsulas lipidìcas furtivas, processos para a preparação das mesmas e uso das mesmas como um veìculo para princìpio(s) ativo(s)

Country Status (13)

Country Link
US (1) US20050214378A1 (de)
EP (1) EP1531800B1 (de)
JP (1) JP2005532355A (de)
CN (1) CN1658845A (de)
AU (1) AU2003247061B2 (de)
BR (1) BR0314767A (de)
CA (1) CA2488385A1 (de)
IL (1) IL165603A (de)
MX (1) MXPA04012567A (de)
NO (1) NO333811B1 (de)
NZ (1) NZ537393A (de)
WO (1) WO2003103822A2 (de)
ZA (1) ZA200500228B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085337A1 (en) 2001-04-20 2002-10-31 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
JP4886297B2 (ja) 2002-11-01 2012-02-29 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド ジオデート送達媒体
FR2864900B1 (fr) * 2004-01-09 2007-10-12 Oreal Dispersion aqueuse de nanocapsules a coeur huileux
WO2005079856A1 (en) * 2004-02-23 2005-09-01 The University Of British Columbia Drug delivery compositions comprising hydrophobic polymers and amphipathic molecules
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
JP5303269B2 (ja) * 2005-06-06 2013-10-02 学校法人早稲田大学 骨髄指向性薬物送達物質およびその用途
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
DK2076244T3 (en) * 2006-10-10 2017-02-27 Jina Pharmaceuticals Inc Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods and uses thereof
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
KR101518077B1 (ko) 2006-12-01 2015-05-28 안테리오스, 인코퍼레이티드 펩티드 나노입자 및 이의 용도
EP1932516A1 (de) * 2006-12-11 2008-06-18 Universiteit Utrecht Holding B.V. Zusammensetzungen enthaltend antientzündliche Verbindungen zur Behandlung von Krebs
EP1946747A1 (de) * 2007-01-17 2008-07-23 Sandoz AG Taxanderivat enthaltende pharmazeutische Zusammensetzung von verbesserter Stabilität
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
EP2036577A1 (de) 2007-09-14 2009-03-18 mivenion GmbH Diagnostische Stoffe für die optische bildgebende Untersuchung auf der Basis von nanopartikulären Formulierungen
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2010018596A2 (en) * 2008-07-23 2010-02-18 Bharat Serums And Vaccines Ltd. Stable injectable oil-in-water docetaxel nanoemulsion
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
FR2939699B1 (fr) 2008-12-12 2011-05-06 Univ Angers Procede de preparation de nanoparticules lipidiques
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
US20110166214A1 (en) 2010-01-07 2011-07-07 Innopharma, Llc Methods and compositions for delivery of taxanes in stable oil-in-water emulsions
KR101769666B1 (ko) 2015-04-13 2017-08-21 영남대학교 산학협력단 독소루비신 및 이리노테칸을 포함하는 항암용 약학 조성물 및 이의 제조방법
CN105213313B (zh) * 2015-11-17 2018-08-14 西安力邦肇新生物科技有限公司 一种地西他滨长循环脂质体冻干制剂及其制备方法
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
JPWO2018180966A1 (ja) * 2017-03-28 2019-06-27 富士フイルム株式会社 マイクロカプセル及びその製造方法
GB201721832D0 (en) 2017-12-22 2018-02-07 Waterford Institute Of Tech Ocular drug delivery
JP2022537042A (ja) * 2019-06-21 2022-08-23 ウニベルシテ カソリーク デ ルーベン インクレチンミメティックが装填された脂質ナノカプセル
CN112773776B (zh) * 2019-11-11 2023-06-20 上海胜联医药科技有限公司 一种载药纳米粒体系

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament

Also Published As

Publication number Publication date
MXPA04012567A (es) 2005-04-19
EP1531800B1 (de) 2011-06-08
IL165603A (en) 2008-08-07
CA2488385A1 (en) 2003-12-18
WO2003103822A2 (en) 2003-12-18
EP1531800A2 (de) 2005-05-25
NO20050153L (no) 2005-01-11
AU2003247061A1 (en) 2003-12-22
JP2005532355A (ja) 2005-10-27
IL165603A0 (en) 2006-01-15
CN1658845A (zh) 2005-08-24
ZA200500228B (en) 2005-09-28
WO2003103822A3 (en) 2004-03-25
US20050214378A1 (en) 2005-09-29
NO333811B1 (no) 2013-09-23
AU2003247061B2 (en) 2008-10-09
NZ537393A (en) 2007-01-26

Similar Documents

Publication Publication Date Title
BR0314767A (pt) Nanocápsulas lipidìcas furtivas, processos para a preparação das mesmas e uso das mesmas como um veìculo para princìpio(s) ativo(s)
BRPI0516259A (pt) composto de copolìmero em bloco, copolìmero em bloco, nano-cápsula, processo para manufaturar o copolìmero em bloco, uso do copolìmero em bloco, método para encapsular e/ou associar com pelo menos um agente funcional lipofìlico, e, produto perfumado
DE60104206D1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
BR0314354A (pt) Formação para gentes lipofìlicos
BR9916642A (pt) Método e composição de substrato para uso no isolamento de irritantes cutâneos
WO2007050543A3 (en) Topical pharmaceutical foam composition
WO2004045572A8 (en) Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil
CA2322506A1 (en) Tissue paper having antimicrobial skin lotion
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
BRPI0207215B8 (pt) Derivados de pirazolopirimidinona tendo ação de inibição de pde7
JP2002284702A (ja) 外用抗真菌製剤
ATE511834T1 (de) Stealth lipid-nanokapseln, verfahren zu ihrer herstellung und ihre verwendung als träger von wirkstoff(en)
BR0316776A (pt) Formula para anti-infeccioso tópico
BR9813811A (pt) "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo"
MX17808A (es) Nuevos derivados de artemisinina,procedimiento para su preparacion y su uso como agentes antiprosoos
EP1179352A1 (de) Topische Zusammensetzung zur Bedeckung von Hautverletzungen
EE05422B1 (et) Klaritromtsiini, rasv- ja hdrofiilse komponendi segu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine
MXPA04005783A (es) Formulacion farmaceutica que comprende ciclosporina y uso de la misma.
DE50012930D1 (de) Emulgatorfreie feindisperse systeme vom typ wasser-in-öl
ATE373466T1 (de) Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
KR20150105290A (ko) 외용 첩부제
WO2003018059A3 (de) Kombinationspräparate von arylsubstituierten propanolaminderivaten mit weiteren wirkstoffen und deren verwendung
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
BRPI0309943B8 (pt) composição aquosa de enxágue condicionadora dos cabelos e seu uso
BRPI0016441B1 (pt) composição de tratamento de cabelo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.